⚠ Building Capacity Is a Bet on Lasting DemandModerate threat

Lilly is spending tens of billions of dollars to build manufacturing capacity for its incretins, and that enormous, long-lead investment is a bet that demand will remain high enough, for long enough, to justify it. Factories take years to build and are expensive to idle; committing this much capital assumes the extraordinary current demand persists at scale well into the future. If that assumption proves wrong — if demand softens, competition captures share, or cheaper alternatives shift the market — Lilly could be left with costly excess capacity built for a boom that faded.

The danger is the timeless hazard of capacity investment in a hot market: the tendency to build for peak demand just as the peak passes. Supply constraints are being relieved not only by Lilly but by Novo and others expanding aggressively, so the industry as a whole is adding capacity into the same demand; if it collectively overbuilds, or the market matures faster than expected, today's shortage could become tomorrow's glut, pressuring prices and stranding investment.

Lilly's investment looks well-justified by demand that remains far ahead of supply, and expanding capacity is exactly the right move while patients wait — the bet is a sensible one. But an owner should recognize that huge, irreversible capacity commitments are inherently risky, that they assume a durable demand no one can guarantee, that the whole industry is building at once, and that the same investment which captures today's supply-constrained demand would become a costly burden if that demand ever fails to materialize as planned — ~$50B of concrete is a large thing to be wrong about¹.